I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2016; Reaffirms Earnings Guidance for the Fiscal Year Ending March 31, 2017
February 12, 2017
Share
I'rom Group Co., Ltd. reported consolidated earnings results for the nine months ended December 31, 2016. For the period, the company reported net sales of JPY 2,972 million against JPY 2,702 million a year ago. Operating loss was JPY 241 million against JPY 649 million a year ago. Ordinary loss was JPY 193 million against JPY 957 million a year ago. Net loss attributable to owners of parent was JPY 212 million against JPY 974 million a year ago. Net loss per share was JPY 19.86 against JPY 91.79 a year ago.
For the fiscal year ending March 31, 2017, on consolidated basis, the company expects net sales of JPY 7,200 million, operating income of JPY 600 million, ordinary income of JPY 700 million and net income attributable to owners of parent of JPY 500 million or JPY 47.12 per share.
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2016; Reaffirms Earnings Guidance for the Fiscal Year Ending March 31, 2017